In today’s briefing:
- Perfect Medical Revisited: What Worked, What Did Not, and What 9x Earnings Means Today
- AMD @ Citi Global TMT Conference. Key Takeaways & Full Transcript
- Fast Retailing (9983) | Pullback Closes Valuation Gap
- Tesco (TSCO LN): Synthetic Expert Call Transcript (09 Sep 2026)
- Want Want China (151 HK): Synthetic Expert Call Transcript (09 Sep 2026)
- Kanohar Electricals IPO Review
- Sirnaomics Ltd: Every Approved SiRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer
- Info-Tech Systems Limited 1HFY2026 Results Update
- Boeing Paid $8.4 Billion To Fix Its Own Problem!
- TCS (TCS IN) Vs Infosys (INFO IN): IT Giants Hit Pair Trade Trigger
Perfect Medical Revisited: What Worked, What Did Not, and What 9x Earnings Means Today
- Our 2020 thesis correctly identified Perfect Medical’s cash generation and management discipline, but underestimated how narrow and execution-dependent its moat was.
- The full financial history shows resilience rather than compounding: overseas expansion disappointed, margins compressed sharply, and competitive pressure remained persistent.
- At roughly 9x FY03/2026 earnings with an 11% trailing dividend yield, the stock is interesting again – but the thesis is now stabilization and cash return.
AMD @ Citi Global TMT Conference. Key Takeaways & Full Transcript
- On the CPU side, after a supply constraint, we have been increasing supply. We expect the second‑half CPU business to expand more than 80 % year‑over‑year,
- CPU will continue expanding more than 70 % next year though it will still remain supply‑constrained
- We just updated our TAM opportunities to more than $220 billion from $25 billion in 2025. That is how significant the expansion has been.
Fast Retailing (9983) | Pullback Closes Valuation Gap
- Valuation gap has closed; move to Neutral despite intact underlying fundamentals.
- International growth remains strong, but incremental margin leverage is less certain.
- FY27 guidance is the key catalyst: Japan traffic and International margins are the swing factors.
Tesco (TSCO LN): Synthetic Expert Call Transcript (09 Sep 2026)
- The structural stickiness of Tesco’s recent 28.7% market share is primarily defensive rather than organic expansion, heavily sustained by matching discounters on price (via 600+ Aldi Price Match lines) and using high-margin Tesco Finest (£3.0 billion in sales) to offset low-margin staple matches.
- Retail media represents a highly lucrative but mathematically capped revenue driver, with blended margins of 50-60% run via Tesco Media & Insight Group (Dunnhumby). The structural ceiling is estimated to be around 1.5% of gross sales (~£1.0 billion in revenue), meaning retail media is a margin-stabilizer against wage growth rather than an infinite expansion engine.
- Tesco’s Urban Fulfillment Center (UFC) rollout has experienced substantial diminishing returns, with escalating CapEx costs (£5.0 million to £5.5 million per site) and deployment delays limiting the active network to just around 7 operational units. Instead of full-automation, Tesco is relying on manual, route-optimized “dotcom” picking and rapid-delivery partnerships (e.g., Uber Eats / Whoosh) to preserve its medium-term ROIC targets.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Want Want China (151 HK): Synthetic Expert Call Transcript (09 Sep 2026)
- The “Split-Brain” Strategy and Crisis: Want Want China is experiencing an operational bottleneck, highlighted by Chairman Tsai Eng-meng’s August 2026 internal letter calling their 38% Q1 profit plunge a “major operating crisis”. Senior management is paralyzed: they are pushing the R&D team to innovate sugar-free and healthy products, while concurrently incentivizing the sales force to dump legacy, high-sugar, high-margin products like Want Want Milk to meet aggressive short-term volume targets.
- Channel Conflict and Cannibalization: Legacy traditional wholesale channels (which historically represented the core of Want Want’s business) are in a structural decline, down high single-digits. The rapid expansion into hard-discount specialty snack retail (now representing 15% of total revenue) is cannibalizing traditional distributors. Lower-tier distributor channel inventory has ballooned from a healthy 30-day baseline to a dangerous 90 to 100 days.
- Macro and Raw Material Pressures: Recent margin erosion is structural rather than cyclical. Spiking raw materials—with global sugar hitting a multi-month high above 18.36 cents per pound and palm oil hovering around RM 4,966 per tonne—are colliding with high internal M&A hurdle rates (WACC of 15%) that prevent the company from acquiring healthy snack brands defensively, leaving them trapped with declining legacy assets.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Kanohar Electricals IPO Review
- Kanohar Electricals (KANOHAR IN) , a Meerut based transformer and EPC company, opens its INR 1,055.74 crore IPO on September 8, 2026, priced at INR 601–632 a share.
- The company has grown revenue 2.4x in two years on the back of a 500 MVA, 400kV order from Power Grid, but customer concentration and capacity utilisation remain watch points.
- IPO looks aggressively priced as compared to other listed company in similar space.
Sirnaomics Ltd: Every Approved SiRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer
- VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share.
- Sirnaomics develops siRNA medicines, drugs that silence a disease-causing gene before it is turned into protein. The hard part is delivery, and beyond the liver very few groups can do it. The company owns two platforms: PNP, which it places among the world’s few extra-hepatic siRNA delivery systems with clinically proven safety, and GalAhead, which it describes as the only programmable RNAi platform for dosing intervals in global clinical development. Four programmes are in human trials, a fifth is IND-ready, and the company holds global rights across them.
- The five years since listing were costly. Accumulated losses reached US$536.8m, spending was cut from US$91.8m in 2022 to US$15.3m in 2025, and headcount fell from 225 to 37. The audit opinion is qualified and going concern is flagged.
Info-Tech Systems Limited 1HFY2026 Results Update
- Info-Tech System’s (ITS) Services revenue rose from S$5.3m in FY2024 to S$15.0m in FY2025, a rise of S$9.7m against a group rise of S$12.8m, so services contributed 76% of what the group added that year.
- The five filed six-month periods put that rise in one of them: Services reached S$12.7m in the 2HFY2025 and came back to S$4.9m in 1HFY2026 a fall of 61%, while group revenue fell 20%.
- The FY2025 increase sits in one six-month period and in one revenue heading, and it has not happened again.
Boeing Paid $8.4 Billion To Fix Its Own Problem!
- Boeing is attempting one of the most expensive corporate U-turns in modern aerospace.
- Two decades after separating the manufacturing operations that became Spirit AeroSystems, Boeing completed an $8.4 billion acquisition of the struggling supplier in December 2025, bringing critical fuselage production back under its roof.
- The timing is striking.
TCS (TCS IN) Vs Infosys (INFO IN): IT Giants Hit Pair Trade Trigger
- Context: The Tata Consultancy Services (TCS IN) vs. Infosys (INFO IN) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.
- Highlight: Going long Infosys Ltd (INFO IN) and short Tata Consultancy Services (TCS IN) targets a 3% return.
- Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
